Acumen doses first patient in Phase II Alzheimer’s disease trial

Acumen doses first patient in Phase II Alzheimer’s disease trial

Submitted by admin on May 9, 2024 - 7:16pm
Source: 
Clinical Trials Arena
News Tags: 
Acumen Pharmaceuticals
clinical trials
sabirnetug
Alzheimer's disease
Headline: 
Acumen doses first patient in Phase II Alzheimer’s disease trial
snippet: 

Acumen Pharmaceuticals has dosed the first patient in ALTITUDE-AD, a Phase II trial designed to evaluate the clinical efficacy and safety of its lead drug sabirnetug (ACU193) in patients with early Alzheimer’s disease.

Do Not Allow Advertisers to Use My Personal information